Marchesini Giulio, Marzocchi Rebecca
Unit of Metabolic Diseases, Department of Internal Medicine and Gastroenterology, Alma Mater Studiorum University of Bologna, Policlinico S. Orsola, Bologna, Italy.
Clin Liver Dis. 2007 Feb;11(1):105-17, ix. doi: 10.1016/j.cld.2007.02.013.
Clinical and epidemiologic studies have associated non-alcoholic fatty liver with the metabolic syndrome, with insulin resistance as the pivotal pathogenic factor. Obesity, type 2 diabetes mellitus, dyslipidemia, and hypertension contribute to risk for liver disease and to disease progression. The presence of multiple metabolic abnormalities is associated with the severity of liver disease. Patients have a high risk for cardiovascular morbidity and mortality, mediated by early atherosclerosis. This evidence has precise therapeutic implications: only a behavioral approach to lifestyle correction will address all alterations characterizing the metabolic syndrome, including metabolic liver disease.
临床和流行病学研究已将非酒精性脂肪肝与代谢综合征联系起来，其中胰岛素抵抗是关键的致病因素。肥胖、2型糖尿病、血脂异常和高血压会增加肝病风险并促使疾病进展。多种代谢异常的存在与肝病的严重程度相关。患者因早期动脉粥样硬化而有较高的心血管发病和死亡风险。这一证据具有明确的治疗意义：只有通过行为方式纠正生活方式，才能解决代谢综合征所具有的所有改变，包括代谢性肝病。
